• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

创建和使用真实世界证据来回答有关临床疗效的问题。

Creating and using real-world evidence to answer questions about clinical effectiveness.

作者信息

de Lusignan Simon, Crawford Laura, Munro Neil

机构信息

University of Surrey, Guildford, UK.

出版信息

J Innov Health Inform. 2015 Nov 4;22(3):368-73. doi: 10.14236/jhi.v22i3.177.

DOI:10.14236/jhi.v22i3.177
PMID:26577427
Abstract

New forms of evidence are needed to complement evidence generated from randomised controlled trials (RCTs). Real-World Evidence (RWE) is a potential new form of evidence, but remains undefined. This paper sets to fill that gap by defining RWE as the output from a rigorous research process which: (1) includes a clear a priori statement of a hypothesis to be tested or research question to be answered; (2) defines the data sources that will be used and critically appraises their strengths and weaknesses; and (3) applies appropriate methods, including advanced analytics. These elements should be set out in advance of the study commencing, ideally in a published protocol.The strengths of RWE studies are that they are more inclusive than RCTs and can enable an evidence base to be developed around real-world effectiveness and to start to address the complications of managing other real-world problems such as multimorbidity. Computerised medical record systems and big data provide a rich source of data for RWE studies. However, guidance is needed to help assess the rigour of RWE studies so that the strength of recommendations based on their output can be determined. Additionally, RWE advanced analytics methods need better categorisation and validation.We predict that the core role of RCTs will shift towards assessing safety and achieving regulatory compliance. RWE studies, notwithstanding their limitations, may become established as the best vehicle to assess efficacy.

摘要

需要新的证据形式来补充随机对照试验(RCT)产生的证据。真实世界证据(RWE)是一种潜在的新证据形式,但仍未明确界定。本文旨在通过将RWE定义为严格研究过程的产出,来填补这一空白,该过程包括:(1)对要检验的假设或要回答的研究问题有明确的先验陈述;(2)定义将使用的数据来源,并严格评估其优缺点;(3)应用适当的方法,包括高级分析。这些要素应在研究开始前确定,理想情况下应在已发表的方案中列出。RWE研究的优势在于,它们比RCT更具包容性,能够围绕真实世界的有效性建立证据基础,并开始解决管理其他真实世界问题(如多种疾病并存)的复杂性。计算机化医疗记录系统和大数据为RWE研究提供了丰富的数据来源。然而,需要指导来帮助评估RWE研究的严谨性,以便确定基于其产出的推荐强度。此外,RWE高级分析方法需要更好的分类和验证。我们预测,RCT的核心作用将转向评估安全性和实现监管合规。RWE研究尽管有其局限性,但可能会成为评估疗效的最佳手段。

相似文献

1
Creating and using real-world evidence to answer questions about clinical effectiveness.创建和使用真实世界证据来回答有关临床疗效的问题。
J Innov Health Inform. 2015 Nov 4;22(3):368-73. doi: 10.14236/jhi.v22i3.177.
2
The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.真实世界证据在慢性髓性白血病临床研究未来中的应用。
Clin Ther. 2019 Feb;41(2):336-349. doi: 10.1016/j.clinthera.2018.12.013. Epub 2019 Jan 30.
3
Translational hurdles with cannabis medicines.大麻药物转化的障碍。
Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1325-1330. doi: 10.1002/pds.4999. Epub 2020 Apr 12.
4
Procedures and methods of benefit assessments for medicines in Germany.德国药品效益评估的程序和方法。
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
5
[Procedures and methods of benefit assessments for medicines in Germany].[德国药品效益评估的程序和方法]
Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25.
6
Making Clinical Practice Guidelines Pragmatic: How Big Data and Real World Evidence Can Close the Gap.制定实用的临床实践指南:大数据和真实世界证据如何缩小差距。
Ann Acad Med Singap. 2018 Dec;47(12):523-527.
7
Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?真实世界证据:在美国医保支付方决策的现实世界中有用吗?如何有用?何时有用?以及哪些研究有用?
Value Health. 2018 Mar;21(3):326-333. doi: 10.1016/j.jval.2017.08.3013. Epub 2017 Oct 18.
8
Emerging opportunities to harness real world data: An introduction to data sources, concepts, and applications.利用真实世界数据的新兴机会:数据源、概念和应用介绍。
Diabetes Obes Metab. 2020 Apr;22 Suppl 3:3-12. doi: 10.1111/dom.13948.
9
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.提高透明度以建立对假设检验的真实世界二次数据研究的信任——原因、内容和方法:来自真实世界证据透明度倡议的建议和路线图。
Value Health. 2020 Sep;23(9):1128-1136. doi: 10.1016/j.jval.2020.04.002.
10
Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?真实世界证据(RWE)——是颠覆性创新还是医学证据生成的悄然演进?
F1000Res. 2018 Jan 25;7:111. doi: 10.12688/f1000research.13585.2. eCollection 2018.

引用本文的文献

1
Real-World Comparison of Telemonitoring Versus Conventional Care in Patients With Chronic Obstructive Pulmonary Disease and Those With Asthma-Impact on Clinical Outcomes and Patient Characteristics: Retrospective Cohort Study.慢性阻塞性肺疾病和哮喘患者远程监测与传统护理的真实世界比较:对临床结局和患者特征的影响:回顾性队列研究。
J Med Internet Res. 2025 Aug 14;27:e66743. doi: 10.2196/66743.
2
Real-world evidence in gynecologic cancers presented at key oncology conferences in the United States: Distribution and factors related to high-tier acceptance.在美国主要肿瘤学会议上展示的妇科癌症真实世界证据:与高级别接受度相关的分布及因素
PLoS One. 2025 Apr 22;20(4):e0321654. doi: 10.1371/journal.pone.0321654. eCollection 2025.
3
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring exon 14 skipping treated with systemic therapy.
MOMENT注册研究:接受全身治疗的携带14号外显子跳跃突变的晚期非小细胞肺癌患者。
J Comp Eff Res. 2025 Feb;14(2):e240127. doi: 10.57264/cer-2024-0127. Epub 2025 Jan 21.
4
A Response to: Letter to the Editor Regarding "Comparing Cardiovascular Outcomes and Costs of Perindopril-, Enalapril- or Losartan-Based Antihypertensive Regimens in South Africa: Real-World Medical Claims Database Analysis".对《致编辑的信:关于“南非基于培哚普利、依那普利或氯沙坦的降压方案的心血管结局与成本比较:真实世界医疗索赔数据库分析”》的回应
Adv Ther. 2025 Jan;42(1):552-555. doi: 10.1007/s12325-024-03045-y. Epub 2024 Nov 19.
5
Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study.探索西班牙真实世界实践中不符合移植条件的新诊断多发性骨髓瘤的治疗:CARINAE研究
Pharmaceuticals (Basel). 2024 Sep 26;17(10):1272. doi: 10.3390/ph17101272.
6
Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population.亚洲人群中激素受体阳性转移性和复发性乳腺癌中 CDK4/6 抑制剂的真实世界经验:来自亚洲人群的研究结果。
Clin Exp Med. 2024 Aug 12;24(1):185. doi: 10.1007/s10238-024-01458-1.
7
A comparison of sodium-glucose co-transporter 2 inhibitor kidney outcome trial participants with a real-world chronic kidney disease primary care population.钠-葡萄糖协同转运蛋白2抑制剂肾脏结局试验参与者与真实世界慢性肾脏病初级保健人群的比较。
Nephrol Dial Transplant. 2024 Dec 20;40(1):71-82. doi: 10.1093/ndt/gfae071.
8
The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR.真实世界证据在治疗决策、监管评估及理解2型糖尿病患者观点中的作用:以格列齐特缓释片为例
Diabetes Ther. 2023 Oct;14(10):1609-1625. doi: 10.1007/s13300-023-01458-6. Epub 2023 Aug 21.
9
Comparative effects of desflurane and sevoflurane on intraoperative peripheral perfusion index: a retrospective, propensity score matched, cohort study.地氟醚和七氟醚对术中外周灌注指数影响的比较:一项回顾性、倾向评分匹配的队列研究。
Sci Rep. 2023 Mar 6;13(1):2991. doi: 10.1038/s41598-022-27253-0.
10
Real-world data in oncology: a questionnaire-based analysis of the academic research landscape examining the policies and experiences of the cancer cooperative groups.肿瘤学真实世界数据:一项基于问卷调查的学术研究现状分析,旨在探讨癌症合作组的政策和经验。
ESMO Open. 2023 Apr;8(2):100878. doi: 10.1016/j.esmoop.2023.100878. Epub 2023 Feb 21.